×
Abstract P2-10-04: Targeted sequencing in early breast cancer: Identification of novel candidate mutations predictive of anthracycline benefit
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-10-04

Jul 2nd, 2018 - Background The use of chemotherapies such as anthracyclines and taxanes have improved overall and disease free survival in breast cancer. For all patients, anthracyclines can have significant toxicities including cardiotoxicity and leukemia. It is therefore essential to select the subset of patients who will receive the optimal overall benefit from anthracycline therapy and to identify molecula...

Abstract P5-23-04: Men with advanced breast cancer (BC): Initial phase (Ph) 2 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-23-04

Oct 24th, 2018 - Background: Seviteronel (Sevi), an oral selective CYP17-lyase and AR inhibitor that blocks testosterone and estradiol production whilst competitively antagonizing the AR, is in Ph 2 clinical development for the treatment of advanced prostate and breast cancers (BC). Male BC is a high unmet need. Men with BC have a high rate of advanced disease at the time of diagnosis and disease-related deaths...

Abstract P2-10-07: A prospective clinical utility study of the impact of the 21-gene recurrence score (RS) assay in the treatment of estrogen receptor positive (ER+), HER2 negative (HER2-), 1-3 nod...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-10-07

Jul 9th, 2018 - Background: The 21-gene RS is routinely used in node negative ER+, HER2- BC to help guide chemotherapy treatment decision making. There is emerging use of the RS in limited N+ BC, though the results from the randomized clinical trial (RxPONDER) is pending. The objective of the study is to determine whether the results of the 21-gene RS will alter physician treatment decisions in ER+ HER2- limit...

Abstract P5-23-01: Clinical and biological characterization of male breast cancer (BC) EORTC 10085/TBCRC 029/BOOG 2013-02/BIG 2-07: Baseline results from the prospective registry
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-23-01

Oct 25th, 2018 - BACKGROUND: Through the International Male Breast Cancer Program, a prospective registry for male BC was created with the goals of evaluating 1) the clinical and biological features of this disease and 2) assessing feasibility of a prospective therapeutic clinical trial. METHODS: All men, with any stage histologically proven invasive breast cancer, age 3 18 years, and newly presenting at the pa...

Abstract P4-09-07: Validation of 12-gene chemokine signature as a predictor of treatment response in breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-09-07

Jul 13th, 2018 - Background: We had previously derived a unique 12-chemokine gene expression score (CS) from a metagene grouping with high enrichment for immune-and inflammation-related genes. A review of selected Stage I - III breast cancer patients showed that higher CS were associated with high-grade tumors and aggressive subtypes and in the HER2 positive group, correlated with increased recurrence free surv...

Abstract P4-09-02: Disseminated tumor cells as predictive factor of benefit of lymph node irradiation to prevent loco-regional relapse
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-09-02

Jul 10th, 2018 - Background: Early stage breast cancer patients with micrometastatic spread (cM0(i+) per the 2010 TNM staging), detected either in the bone marrow (disseminated tumor cells, DTC) or in the blood (circulating tumor cells, CTC) are at higher risk of distant relapse and death. Loco-regional relapses were also more frequently observed in patients with DTC and, recently, with CTC (IMENEO study, Bidar...

Abstract P5-23-06: Metastatic pattern in stage IV male breast cancer at initial diagnosis: A population-based study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-23-06

Oct 27th, 2018 - Background: Male breast cancer (MaBC) is a relatively uncommon disease, representing less than 1% of all breast cancers. Although men tend to present at more advanced stages, the prognostic influence of metastatic pattern (MP), sites of metastases and factors associated with specific organ involvement are unknown. The primary aim of this study was to analyze the influence of MP compared with ot...

Abstract P5-11-01: The accuracy of nomograms based on large dataset using clinico-pathologic variables for prediction of oncotype DX breast cancer recurrence score
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-11-01

Jul 18th, 2018 - Purpose The 21 gene expression assay, Oncotype DX (ODX) is costly (the current estimated cost is ˜$4000), and were tested in only approximately one-third of breast cancer patients who meet the inclusion criteria in the United States. Recent study of University of Tennessee Medical Center reported a novel nomogram for prediction of ODX recurrence score using clinico-pathologic data, which was ba...

Abstract P4-08-07: PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ERα serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-posit...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-08-07

Jul 25th, 2018 - Background: Endocrine therapy is the most important treatment option for women with estrogen receptor (ER)-positive breast cancer. We recently reported that approximately two-thirds of patients who relapsed within 5 years had received anthracyclins and/or taxanes as adjuvant or neoadjuvant chemotherapy in addition to adjuvant endocrine therapy. New strategies, such as signal transduction inhibi...

Abstract P4-03-04: Targeting the mevalonate pathway in HER2-positive breast cancer to overcome resistance to anti-HER2 therapy
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-03-04

Jan 27th, 2019 - Background: Despite the advent of HER2-targeted therapies for HER2+ breast cancer (BC), including the monoclonal antibody trastuzumab (T) either alone or in combinations, resistance still poses a major clinical challenge. Using our broad panel of HER2+ cell lines made resistant (R) to T alone (TR), and to lapatinib plus T (LTR), we observed that in resistant models where HER2 remains inhibited,...

Abstract P1-06-01: Putting multigene signatures to the test: Prognostic assessment in population-based contemporary clinical breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-01

Jul 29th, 2018 - Background Gene expression signatures hold promise for a molecularly driven division of primary breast cancer with clinical implications. A gap still remains in the application/validation of such signatures in actual clinical treatment groups from unselected, population-based, primary breast cancer receiving current standard of care therapy. We analyzed classification proportions and overall su...

Abstract P4-08-08: Biomarkers to predict distant recurrence free survival after neoadjuvant endocrine therapy in breast cancer. A long follow up retrospective study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-08-08

Jul 26th, 2018 - Background: Neoadjuvant endocrine therapy (NET) is gaining more acceptances for the management of estrogen receptor (ER) positive breast cancer (BC). Rate of patients achieving pathological complete response is very low and Ki67 suppression and PEPI score are the only prognostic factors associated with relapse free survival. The aim of our study was to identify biomarkers of prediction of dista...

Abstract P3-13-04: Change in oncotype DX variables and Ki67 response and outcome in women with ER positive early breast cancer treated with neo-adjuvant anastrozole and fulvestrant
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-13-04

Oct 31st, 2018 - Neo-adjuvant endocrine therapy (NAET) provides opportunity for on-treatment assessment of endocrine responsiveness and need for adjuvant chemotherapy (C) in ER+/HER2 negative breast cancer (BC). We investigated Ki67-IHC response to NAET, the 21-gene Recurrence Score (RS; Oncotype DX), and Postoperative Endocrine Prognostic Index (PEPI) as predictors of response and recurrence in a neoadjuvant t...

Abstract P1-06-06: No age-related outcome disparities according to 21-gene recurrence score groups in early breast cancer patients treated by adjuvant chemotherapy in the prospective WSG PlanB trial
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-06

Aug 2nd, 2018 - Background: Elderly breast cancer (BC) patients (pts) have been reported to have worse BC-related outcome than younger pts, even within clinical trials such as TEAM. Shak et al. recently showed in a large SEER data analysis that in the high 21-gene recurrence score (RS) group, older pts (>70y) receive less chemotherapy (CT) and have a worse BC-specific mortality than younger pts. Here, we there...

Abstract P1-06-04: Simplified histological grading of breast carcinoma – potential for improved concordance and consistency in breast cancer grading?
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-04

Aug 3rd, 2018 - Histological grade remains an independent predictor of outcome for invasive breast cancer. The internationally accepted standard grading system is the Elston and Ellis grading system based on a local hospital (Nottingham) cohort treated between 1951-1973. Histological grade, with nodal status, tumour size and receptor measurements (ER, PgR, HER2) give important information even in the context o...

Abstract P1-10-13: Olaparib nanoformulation in H-ferritin as a promising option for both BRCA-mutated and sporadic triple negative breast cancer: An in vitro study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-10-13

Nov 3rd, 2018 - Background: PolyADP-ribose polymerase (PARP) inhibitors are a novel promising strategy toward triple-negative breast cancer (TNBC), which often shows genomic instability or BRCA mutations. However, clinical results are controversial, and no benefits were demonstrated in case of wild type BRCA, possibly due to poor bioavailability, and inadequate nuclear delivery. Nanotechnology could overcome t...

Abstract P1-10-15: Development of humanized anti-CD47 monoclonal antibodies with differentiated functional profiles
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-10-15

Nov 4th, 2018 - CD47 is a cell surface transmembrane protein that binds to signal regulatory protein alpha (SIRPα) on macrophages and results in a “don't eat me” signal that inhibits phagocytosis. Breast cancer cells, both primary and metastatic, frequently overexpress CD47 and exploit this pathway to evade macrophage-mediated destruction. Anti-CD47 monoclonal antibodies (mAbs) block the CD47/SIRPα interaction...

Abstract P4-03-14: OTULIN promotes resistance and metastasis upon chemotherapy in TNBC by activating Wnt/β-catenin signaling
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-03-14

Feb 2nd, 2019 - Triple-negative breast cancer (TNBC) or Basal-like breast cancer is characterized by worse prognosis than other breast cancer subtypes due to the rapid-arising therapeutic resistance accompanied by aggressive metastasis. The therapy-resistant tumor cells, including cancer stem-like cells (CSCs) with intrinsic resistance or tumor cells acquired resistance during treatments, could repopulate the ...

Abstract P3-08-05: Validation of a nomogram for predicting recurrence among women with ductal carcinoma in situ and breast conserving surgery in an integrated health care system
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-08-05

Aug 16th, 2018 - Current management of ductal carcinoma in situ (DCIS) most often entails removing the lesion by breast-conserving surgery. Quantifying the risk of a patient's ipsilateral breast event (IBE) recurrence, either invasive cancer or DCIS, after breast conserving surgery remains a clinical concern. The aim of this study was to validate the Memorial Sloan-Kettering Cancer Center (MSKCC) nomogram to pr...

Abstract P3-08-12: Prognostic relevance of neutrophil-to-lymphocyte ratio (NLR) in young women with breast cancer (BC)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-08-12

Aug 10th, 2018 - Background: Many studies suggest that a high NLR prior to systemic treatment is an adverse prognostic marker for BC but its role in women ≤ age 40 in general, and in those with pregnancy associated BC (PABC) in particular is unknown. We investigated whether the NLR is independently prognostic for recurrence-free survival (RFS) in a prospective database of young BC patients. Methods: A prospecti...